Michael Schomig
Overview
Explore the profile of Michael Schomig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Topf J, Wooldridge T, McCafferty K, Schomig M, Csiky B, Zwiech R, et al.
Kidney Med
. 2022 Aug;
4(8):100512.
PMID: 36016762
Rationale & Objective: Chronic kidney disease-associated pruritus (CKD-aP) in patients treated by hemodialysis (HD) impairs quality of life (QoL). Difelikefalin, a selective κ-opioid receptor agonist, decreased the intensity of CKD-aP...
2.
Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U, et al.
Nephrol Dial Transplant
. 2022 Feb;
37(4):805.
PMID: 35146511
No abstract available.
3.
Csiky B, Schomig M, Esposito C, Barratt J, Reusch M, Valluri U, et al.
Adv Ther
. 2021 Sep;
38(10):5361-5380.
PMID: 34537926
Introduction: Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled...
4.
Barratt J, Sulowicz W, Schomig M, Esposito C, Reusch M, Young J, et al.
Adv Ther
. 2021 Sep;
38(10):5345-5360.
PMID: 34523074
Introduction: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods: Efficacy and safety results from four phase 3, randomized,...
5.
Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U, et al.
Nephrol Dial Transplant
. 2021 Jun;
36(9):1616-1628.
PMID: 34077510
Background: Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). Methods: This randomized, open-label, active-controlled Phase 3 study...
6.
Dikow R, Schwenger V, Schomig M, Ritz E
Nephrol Dial Transplant
. 2002 Jan;
17 Suppl 1:67-72.
PMID: 11812916
Anaemia is an important component of diabetic nephropathy but only recently has it attracted the attention of diabetologists and nephrologists. In diabetic patients, anaemia is the result of diminished erythropoietin...
7.
Schomig M, Ritz E, Standl E, Allenberg J
J Am Soc Nephrol
. 2000 May;
11(6):1153-1159.
PMID: 10820181
No abstract available.